Is it Possible to Predict The Market Access of a New Pharmaceutical in Germany? A Systematic Evaluation of Federal Joint Committee Decisions on Early Benefit Assessments According to The German Law For Reforming The Market of Pharmaceuticals
Publisher: 'Elsevier BV'
DOI identifier: 10.1016/j.jval.2014.08.1135
Sorry, our data provider has not provided any external links therefore we are unable to provide a link to the full text.